Cytospire Therapeutics raised £61 million (about $83 million) in a Series A to advance its pan gamma-delta T-cell engager platform toward clinical proof-of-concept. The company’s lead program, CYT X300, targets EGFR-positive solid tumors and is designed to engage all gamma delta T cells to address heterogeneity while aiming to manage safety and cytokine-release concerns. The round was led by 4BIO Capital and included investors such as Servier Ventures, Sound Bioventures, and the British Business Bank, with participation from Abingworth and LifeArc Ventures. Cytospire plans a first-in-human study in EGFR-positive colorectal, head and neck, and non-small cell lung cancer settings.